End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,340 IDR | +0.37% | -1.47% | -10.07% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 31.27 and 26.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.07% | 1.25B | - | ||
+19.50% | 84.56B | C+ | ||
-27.05% | 72.41B | B- | ||
+2.04% | 27.73B | C+ | ||
-8.18% | 17.75B | B | ||
-1.14% | 17.11B | A- | ||
+5.20% | 16.03B | A- | ||
+71.20% | 13.07B | C- | ||
+6.66% | 12.91B | A- | ||
+71.84% | 12.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HEAL Stock
- Ratings PT Medikaloka Hermina Tbk